AR039367A1 - Compuestos derivados de benzotiazol, nicotina o isonicotina, un proceso para su preparacion, un medicamento que los contiene y uso de los mismos - Google Patents
Compuestos derivados de benzotiazol, nicotina o isonicotina, un proceso para su preparacion, un medicamento que los contiene y uso de los mismosInfo
- Publication number
- AR039367A1 AR039367A1 ARP020104416A ARP020104416A AR039367A1 AR 039367 A1 AR039367 A1 AR 039367A1 AR P020104416 A ARP020104416 A AR P020104416A AR P020104416 A ARP020104416 A AR P020104416A AR 039367 A1 AR039367 A1 AR 039367A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- formula
- compound
- morpholinyl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos derivados de benzotiazol nicotina o isonicotina de fórmula general (1) o (2), en donde: R1 es fenilo, piperidin-1-ilo o morfolinilo; A es -O-; y R es -(CH2)n-N(R'')-C(O)-alquilo inferior, -(C2)n-O-alquilo inferior, -(CH2)n-O-(CH2)n-O-alquilo inferior, alquilo inferior, -(CH2)n-morfolinilo,-(CH2)n-fenilo, -(CH2)n-N(R'')2, -(CH2)n-piridinilo, -(CH2)n-CF3, -(CH2)n-2-oxo-pirrolidinilo o cicloalquilo C4-6; R'' es independientemente uno del otro hidrógeno o alquilo inferior y n es 1 ó 2; ó A es -N(R')-; y R es alquilo inferior, cicloalquilo C4-6, -(CH2)n-O-alquilo inferior, -(CH2)n-piridinilo,-(CH2)n-piperidinilo, -(CH2)n-fenilo, -(CH2)n-N(R'')-C(O)-alquilo inferior, -(CH2)n-morfolinilo, o -(CH2)n-N(R'')2; R' y R'' son independientemente uno del otro hidrógeno o alquilo inferior y n es 1 ó 2; ó A es -CH2-; y R es -N(R'')-(CH2)m-O-alquilo inferior, -N(R'')2, S-alquilo inferior, o es acetidinilo, pirrolidinilo o piperidinilo, que están opcionalmente sustituidos por hidroxilo o alcoxilo inferior o es morfolinilo, -N(R'')-(CH2)m-cicloalquilo C4-6, -N(R'')-(CH2)m-C(O)O-alquilo inferior, -N(R'')-(CH2)m-C(O)OH, -2-oxo-pirrolidinilo, -N(R'')-C(O)O-alquilo inferior, -O(CH2)m-O-alquilo inferior o alcoxilo; R'' es independientemente uno del otro hidrógeno o alquilo inferior y m es 1, 2 ó 3; o A es -S-; y R es alquilo inferior; o A-R son juntos -piperazinilo, sustituido por alquilo inferior, -C(O)-alquilo inferior o un grupo oxo, o es piperidinilo, sustituido por alcoxilo inferior o hidroxilo, o es morfolinilo, sustituido por alquilo inferior, o es cicloalquilo C4-6, -azetidin-1-ilo, opcionalmente sustituido por hidroxilo o alcoxilo inferior, tiomorfolin-1,1-dioxo-tetrahidropirano o 2-oxa-5-aza-biciclo[2.2.1]hept-5-ilo; y las sales farmacéuticamente aceptables de los mismos. Se ha encontrado que los compuestos de fórmula general (1) son ligados del receptor de adenosina. Específicamente, estos compuestos tienen una buena afinidad por el receptor A2A de adenosina y éstos son por lo tanto útiles en el tratamiento de enfermedades relacionadas con este receptor. Estos compuestos son útiles en el control o prevención de enfermedades basadas en la modulación del sistema de la adenosina, tales como la enfermedad de Alzheimer, la enfermedad de Parkinson, la enfermedad de Huntington, neuroprotección, esquizofrenia, ansiedad, dolor, déficits respiratorios, depresión, adicción a las drogas, tales como anfetaminas, cocaína, opioides, etanol, nicotina, canabinoides o contra asma, respuestas alérgicas, hipoxia, isquemia, convulsiones y abuso de sustancias. Además, estos compuestos podrían ser útiles como sedantes, relajantes musculares, antipsicóticos, antiepilépticos, anticonvulsivos y agentes cardioprotectores contra trastornos tales como enfermedad coronaria arterial y paro cardíaco. Las indicaciones más preferibles de acuerdo con la presente son aquellas, que se basan en la actividad antagonista del receptor A2A y que incluye trastornos del sistema nervioso central, por ejemplo el tratamiento o prevención de la enfermedad de Alzheimer, ciertos trastornos depresivos, adición a las drogas, neuroprotección y enfermedad de Parkinson así como ADHD. También se divulga un proceso para su preparación, un medicamento que los contiene y el uso de los mismos. Reivindicación 34: Un proceso para la preparación de un compuesto de fórmula (1) ó (2) tal como se definen en la reivindicación 1, cuyo proceso comprende: a) reacción de un compuesto de fórmula (3) o (4) con un compuesto de fórmula: H-A-R, en presencia de una base para dar un compuesto de fórmula (1) ó (2) en donde R es -(CH2)n-N(R'')-C(O)-alquilo inferior, -(CH2)n-O-alquilo inferior, -(CH2)n-O-(CH2)n-O-alquilo inferior, alquilo inferior, -(CH2)n-morfolinilo, -(CH2)n-fenilo, -(CH2)n-N(R'')2, -(CH2)n-piridinilo, -(CH2)n-CF3, -(CH2)n-2-oxo-pirrolidinilo ó CH4-6-cicloalquilo, Y es cloro o bromo, A es oxígeno ó azufre, y n es 1 ó 2; b) reacción de un compuesto de fórmula (3) ó (4) con un compuesto de fórmula HNRR' para dar un compuesto de fórmula (5) ó (6) en donde R es alquilo inferior, cicloalquilo C4-6, -(CH2)n-O-alquilo inferior, -(CH2)n-piridinilo, -(CH2)n-piperidinilo, -(CH2)n-fenilo, -(CH2)n-N(R'')-C(O)-alquilo inferior, -(CH2)n-morfolinilo ó -(CH2)n-N(R'')2 ó R y R' forman junto con el átomo de N los siguientes grupos: piperazinilo, opcionalmente sustituido con alquilo inferior, C(O)-alquilo inferior ó un grupo oxo, piperidinilo, opcionalmente sustituido por alcoxilo inferior o hidroxilo, morfolinilo, opcionalmente sustituido por alquilo inferior, azetidin-1-ilo, opcionalmente sustituido por hidroxilo o alcoxilo inferior, ó tiomorfolin-1,1-dioxo ó 2-oxa-biciclo[2.21] hept-5-ilo, R' y R'' son independientemente uno del otro hidrógeno o alquilo inferior, Y es cloro o bromo y n es 1 ó 2; ó c) reacción de un compuesto de fórmula (7) ó (8) con un compuesto de fórmula H-R para dar un compuesto de fórmula (9) ó (10) en donde R es -N(R'')-(C2)m-O-alquilo inferior, -N(R'')2, -S-alquilo inferior o es acetidinilo, pirrolidinilo ó piperidinilo, que están opcionalmente sustituidos por hidroxilo ó alcoxilo inferior o es morfolinilo, -N(R'')-(CH2)m-(cicloalquilo C4-6), N(R'')-(CH2)m-C(O)O-alquilo inferior, -N(R'')-(CH2)m-C(O)OH, -2-oxo-pirrolidinilo, -N(R'')-C(O)O-alquilo inferior, -O(CH2)m-O-alquilo inferior o alcoxilo, R'' es independientemente uno del otro hidrógeno o alquilo inferior y m es 1, 2 ó 3, o d) reacción de un compuesto de fórmula (7) ó (8) con un compuesto de fórmula H-O-R para dar un compuesto de fórmula (11) ó (12) en donde R es -(CH2)m-O-alquilo inferior o es alquilo inferior y m es 1, 2 ó 3, ó e) reacción de un compuesto de fórmula (3) ó (4) con un compuesto de fórmula Bu3Sn-A'-R/cat o con B(OH)2-A'-R/cat para dar un compuesto de fórmula (13) ó (14) en donde A'-R son juntos cicloalquenilo C4-6 o dihidopirano e Y es bromo, y entonces reaccionar un compuesto de fórmula (13) ó (14) con hidrógeno y un catalizador para dar el compuesto de fórmula (1) ó (2) en donde A-R son juntos cicloalquilo C4-6 o tetrahidropirano, y si se desea, convertir los compuestos obtenidos en las sales de adición ácida farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01127312 | 2001-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR039367A1 true AR039367A1 (es) | 2005-02-16 |
Family
ID=8179263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020104416A AR039367A1 (es) | 2001-11-19 | 2002-11-18 | Compuestos derivados de benzotiazol, nicotina o isonicotina, un proceso para su preparacion, un medicamento que los contiene y uso de los mismos |
Country Status (38)
Country | Link |
---|---|
US (1) | US6620811B2 (es) |
EP (1) | EP1448198B1 (es) |
JP (1) | JP4226474B2 (es) |
KR (1) | KR100577110B1 (es) |
CN (1) | CN100546580C (es) |
AR (1) | AR039367A1 (es) |
AT (1) | ATE376831T1 (es) |
AU (1) | AU2002351955B2 (es) |
BR (1) | BR0214245A (es) |
CA (1) | CA2467552C (es) |
DE (1) | DE60223278T2 (es) |
DK (1) | DK1448198T3 (es) |
EA (1) | EA007502B1 (es) |
EC (1) | ECSP045109A (es) |
ES (1) | ES2294187T3 (es) |
GT (1) | GT200200232A (es) |
HR (1) | HRP20040396A2 (es) |
HU (1) | HUP0402161A3 (es) |
IL (2) | IL161623A0 (es) |
JO (1) | JO2290B1 (es) |
MA (1) | MA27083A1 (es) |
MX (1) | MXPA04004684A (es) |
MY (1) | MY126176A (es) |
NO (1) | NO20042576L (es) |
NZ (1) | NZ532802A (es) |
PA (1) | PA8558001A1 (es) |
PE (1) | PE20030713A1 (es) |
PL (1) | PL369517A1 (es) |
PT (1) | PT1448198E (es) |
RS (1) | RS39904A (es) |
RU (1) | RU2294933C2 (es) |
SI (1) | SI1448198T1 (es) |
TN (1) | TNSN04087A1 (es) |
TW (1) | TW200407134A (es) |
UA (1) | UA77462C2 (es) |
UY (1) | UY27542A1 (es) |
WO (1) | WO2003043636A1 (es) |
ZA (1) | ZA200403817B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0112395A (pt) * | 2000-06-21 | 2003-07-08 | Hoffmann La Roche | Derivados de benzotiazol |
ES2632544T3 (es) * | 2001-06-07 | 2017-09-14 | Analgesic Neuropharmaceuticals, Llc | Tratamiento de dolor neuropático con el antagonista del receptor de N-metil-D-aspartato (NMDA) dextrometorfano |
EP1763350B1 (en) * | 2004-07-06 | 2011-12-21 | Xenon Pharmaceuticals Inc. | Nicotinamide derivatives and their use as therapeutic agents |
US6734179B2 (en) * | 2001-12-12 | 2004-05-11 | Hoffmann-La Roche Inc. | Benzothiazoles |
US7390813B1 (en) | 2001-12-21 | 2008-06-24 | Xenon Pharmaceuticals Inc. | Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents |
US20050119251A1 (en) * | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
US6872833B2 (en) | 2003-04-14 | 2005-03-29 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
ATE492278T1 (de) * | 2003-07-23 | 2011-01-15 | Synta Pharmaceuticals Corp | Verbindungen gegen entzündungen und immun- relevante verwendungen |
EP1648874B1 (en) | 2003-07-30 | 2011-10-05 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
RU2006112847A (ru) | 2003-09-19 | 2007-11-10 | Ф. Хоффманн-Ля Рош Аг (Ch) | Производные тиазолопиридина в качестве лигандов аденозинового рецептора |
CA2543707A1 (en) * | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
SI3002283T1 (en) | 2003-12-26 | 2018-06-29 | Kyowa Hakko Kirin Co., Ltd. | Thiazole derivatives |
CN1989139B (zh) * | 2004-07-22 | 2010-05-12 | 弗·哈夫曼-拉罗切有限公司 | 苯并噻唑衍生物 |
KR100823799B1 (ko) * | 2004-07-22 | 2008-04-21 | 에프. 호프만-라 로슈 아게 | 벤조티아졸 유도체 |
KR100818028B1 (ko) | 2004-07-22 | 2008-03-31 | 에프. 호프만-라 로슈 아게 | 치환된 벤조티아졸 |
AR051294A1 (es) * | 2004-09-20 | 2007-01-03 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
WO2006034446A2 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridine derivatives for inhibiting human stearoyl-coa-desaturase |
TW200626139A (en) * | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
BRPI0515483A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase |
BRPI0515488A (pt) * | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados de heterocìclicos e seu uso como agentes terapêuticos |
WO2006034440A2 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
TW200626572A (en) * | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
MX2007003332A (es) * | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
EP1814551A2 (en) * | 2004-09-20 | 2007-08-08 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
ES2309814T3 (es) * | 2004-11-05 | 2008-12-16 | F. Hoffmann-La Roche Ag | Proceso para la obtencion de derivados del acido isonicotinico. |
ZA200707896B (en) * | 2005-03-14 | 2009-07-29 | High Point Pharma Llc | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors |
EP2540296A1 (en) * | 2005-06-03 | 2013-01-02 | Xenon Pharmaceuticals Inc. | Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
KR20090064478A (ko) * | 2006-11-13 | 2009-06-18 | 화이자 프로덕츠 인크. | 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도 |
JP2012525389A (ja) | 2009-04-27 | 2012-10-22 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 置換イソキノリン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用方法 |
TWI548411B (zh) | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
UA110097C2 (uk) | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
UA113383C2 (xx) | 2009-09-02 | 2017-01-25 | Терапевтичний агент для лікування тривожних розладів | |
CA2792339A1 (en) * | 2010-03-23 | 2011-09-29 | High Point Pharmaceuticals, Llc | Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors |
JP5248585B2 (ja) * | 2010-12-15 | 2013-07-31 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 治療薬としてのニコチンアミド誘導体およびそれらの使用 |
DE102011005232A1 (de) | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
EA030698B1 (ru) * | 2012-10-02 | 2018-09-28 | Эпитерапьютикс Апс | Ингибиторы деметилаз гистонов |
WO2020103930A1 (zh) * | 2018-11-22 | 2020-05-28 | 上海科技大学 | 噻唑并环类化合物、其制备方法、中间体和应用 |
DE102019110904B4 (de) * | 2019-04-26 | 2022-01-20 | Helmholtz-Zentrum Dresden - Rossendorf E. V. | N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3374550D1 (en) | 1982-12-21 | 1987-12-23 | Johnsen Jorgensen Plastics Ltd | Dispensing container |
FI91859C (fi) | 1987-06-17 | 1994-08-25 | Eisai Co Ltd | Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi |
BR0112395A (pt) * | 2000-06-21 | 2003-07-08 | Hoffmann La Roche | Derivados de benzotiazol |
-
2002
- 2002-11-05 US US10/288,100 patent/US6620811B2/en not_active Expired - Lifetime
- 2002-11-11 PT PT02787632T patent/PT1448198E/pt unknown
- 2002-11-11 CA CA2467552A patent/CA2467552C/en not_active Expired - Fee Related
- 2002-11-11 HU HU0402161A patent/HUP0402161A3/hu not_active Application Discontinuation
- 2002-11-11 WO PCT/EP2002/012562 patent/WO2003043636A1/en active IP Right Grant
- 2002-11-11 RS YU39904A patent/RS39904A/sr unknown
- 2002-11-11 EA EA200400598A patent/EA007502B1/ru not_active IP Right Cessation
- 2002-11-11 CN CNB028228391A patent/CN100546580C/zh not_active Expired - Fee Related
- 2002-11-11 SI SI200230637T patent/SI1448198T1/sl unknown
- 2002-11-11 DE DE60223278T patent/DE60223278T2/de not_active Expired - Lifetime
- 2002-11-11 ES ES02787632T patent/ES2294187T3/es not_active Expired - Lifetime
- 2002-11-11 MX MXPA04004684A patent/MXPA04004684A/es active IP Right Grant
- 2002-11-11 UA UA20040604552A patent/UA77462C2/uk unknown
- 2002-11-11 AU AU2002351955A patent/AU2002351955B2/en not_active Ceased
- 2002-11-11 PL PL02369517A patent/PL369517A1/xx not_active Application Discontinuation
- 2002-11-11 DK DK02787632T patent/DK1448198T3/da active
- 2002-11-11 NZ NZ532802A patent/NZ532802A/en unknown
- 2002-11-11 RU RU2004118425/04A patent/RU2294933C2/ru not_active IP Right Cessation
- 2002-11-11 EP EP02787632A patent/EP1448198B1/en not_active Expired - Lifetime
- 2002-11-11 IL IL16162302A patent/IL161623A0/xx unknown
- 2002-11-11 BR BR0214245-7A patent/BR0214245A/pt not_active IP Right Cessation
- 2002-11-11 AT AT02787632T patent/ATE376831T1/de active
- 2002-11-11 KR KR1020047007638A patent/KR100577110B1/ko not_active IP Right Cessation
- 2002-11-11 JP JP2003545317A patent/JP4226474B2/ja not_active Expired - Fee Related
- 2002-11-14 PA PA20028558001A patent/PA8558001A1/es unknown
- 2002-11-14 TW TW091133371A patent/TW200407134A/zh unknown
- 2002-11-15 PE PE2002001104A patent/PE20030713A1/es not_active Application Discontinuation
- 2002-11-18 JO JO2002114A patent/JO2290B1/en active
- 2002-11-18 UY UY27542A patent/UY27542A1/es not_active Application Discontinuation
- 2002-11-18 MY MYPI20024303A patent/MY126176A/en unknown
- 2002-11-18 GT GT200200232A patent/GT200200232A/es unknown
- 2002-11-18 AR ARP020104416A patent/AR039367A1/es unknown
-
2004
- 2004-04-26 IL IL161623A patent/IL161623A/en not_active IP Right Cessation
- 2004-05-05 HR HR20040396A patent/HRP20040396A2/hr not_active Application Discontinuation
- 2004-05-17 EC EC2004005109A patent/ECSP045109A/es unknown
- 2004-05-18 TN TNP2004000087A patent/TNSN04087A1/en unknown
- 2004-05-18 ZA ZA200403817A patent/ZA200403817B/en unknown
- 2004-05-18 MA MA27681A patent/MA27083A1/fr unknown
- 2004-06-18 NO NO20042576A patent/NO20042576L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR039367A1 (es) | Compuestos derivados de benzotiazol, nicotina o isonicotina, un proceso para su preparacion, un medicamento que los contiene y uso de los mismos | |
ES2898836T3 (es) | Compuestos de amino-naft[1,2-d]imidazol-5-ona 2-sustituida o sales farmacéuticamente aceptables de los mismos | |
BRPI0414266A (pt) | derivados de tiazolopiridina como ligandos receptores da adenosina | |
KR20140113918A (ko) | 루게릭병의 치료 또는 예방에 사용되는 페닐카바메이트 화합물 | |
HUP0302526A2 (hu) | Makrolid vegyületek, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
BRPI0710232B1 (pt) | Composto antagonista do receptor de il-8, composição farmacêutica que compreende o dito composto e uso do mesmo para o tratamento de uma doença mediada por quimiocina | |
HUP0401849A2 (hu) | Kinuklidinszármazékok, ezeket tartalmazó gyógyászati készítmények, továbbá ezek alkalmazása M2 és/vagy M3 muszkarin receptor inhibitorként | |
CN105026360A (zh) | S1p调节剂 | |
JP2005502680A5 (es) | ||
US9688675B2 (en) | 1,7-naphthyridine derivatives | |
RU2004121688A (ru) | 7-аминобензотиазольные производные в качестве лигандов аденозинового рецептора | |
RU2007101052A (ru) | Производные бензотиазола | |
AR037528A1 (es) | Derivados de piridona de benzotiazol | |
EP2590936B1 (en) | Phenylcarbamate compound and muscle relaxant containing the same | |
CN113801073A (zh) | 14-氯-β-榄香烯一氧化氮供体型衍生物及其制备和应用 | |
CN103189350A (zh) | 反式-2-癸烯酸衍生物和含有其的药物 | |
WO2014086098A1 (zh) | 环己烷胺类化合物及其作为抗精神分裂症药物的应用 | |
RU2007101049A (ru) | Замещенные бензотиазолы | |
RU2692808C2 (ru) | Галогенированные хиназолин-thf-амины в качестве ингибиторов pde1 | |
JP2016536320A (ja) | 神経変性疾患の処置用の神経新生薬としてのピリド[4,3−b]ピラジン−2−カルボキサミド | |
AR037457A1 (es) | Compuestos derivados de benzotiazol, su empleo, un procedimiento para prepararlos y medicamentos que los contienen | |
JP4408292B2 (ja) | ベンゾチアゾール誘導体、およびアデノシンa2aレセプターに関連する疾患の処置におけるその使用 | |
AR037792A1 (es) | Compuestos derivados de benzotiazol, su uso, un procedimiento para su obtencion y medicamentos que los contienen | |
TWI601712B (zh) | 作為glyt1抑制劑之經取代之氮雜環丁基化合物 | |
JP7082977B2 (ja) | レスベラトロールのシリル化誘導体および神経変性疾患、神経疾患、または炎症性疾患におけるその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |